These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities. Cousin S; Italiano A Clin Cancer Res; 2016 Sep; 22(18):4550-5. PubMed ID: 27435397 [TBL] [Abstract][Full Text] [Related]
8. Interventional therapy combined with immune checkpoint inhibitors: Emerging opportunities for cancer treatment in the era of immunotherapy. Chang X; Lu X; Guo J; Teng GJ Cancer Treat Rev; 2019 Mar; 74():49-60. PubMed ID: 30831375 [TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint blockade: Releasing the brake towards hematological malignancies. Xia Y; Medeiros LJ; Young KH Blood Rev; 2016 May; 30(3):189-200. PubMed ID: 26699946 [TBL] [Abstract][Full Text] [Related]
11. Immune Checkpoint Inhibitors in Organ Transplant Patients. Kittai AS; Oldham H; Cetnar J; Taylor M J Immunother; 2017 Sep; 40(7):277-281. PubMed ID: 28719552 [TBL] [Abstract][Full Text] [Related]
12. Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validation. Masucci GV; Cesano A; Hawtin R; Janetzki S; Zhang J; Kirsch I; Dobbin KK; Alvarez J; Robbins PB; Selvan SR; Streicher HZ; Butterfield LH; Thurin M J Immunother Cancer; 2016; 4():76. PubMed ID: 27895917 [TBL] [Abstract][Full Text] [Related]
13. Predictive Biomarkers for Checkpoint Immunotherapy: Current Status and Challenges for Clinical Application. Tray N; Weber JS; Adams S Cancer Immunol Res; 2018 Oct; 6(10):1122-1128. PubMed ID: 30279188 [TBL] [Abstract][Full Text] [Related]
14. Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma. Ghatalia P; Zibelman M; Geynisman DM; Plimack ER Curr Treat Options Oncol; 2017 Jan; 18(1):7. PubMed ID: 28210995 [TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors. Hargadon KM; Johnson CE; Williams CJ Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692 [TBL] [Abstract][Full Text] [Related]
16. Inhibitors of the PD-1 Pathway in Tumor Therapy. LaFleur MW; Muroyama Y; Drake CG; Sharpe AH J Immunol; 2018 Jan; 200(2):375-383. PubMed ID: 29311378 [TBL] [Abstract][Full Text] [Related]
17. Immuno-oncologic Approaches: CAR-T Cells and Checkpoint Inhibitors. Gay F; D'Agostino M; Giaccone L; Genuardi M; Festuccia M; Boccadoro M; Bruno B Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):471-478. PubMed ID: 28689001 [TBL] [Abstract][Full Text] [Related]
18. Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma. Maxwell R; Jackson CM; Lim M Curr Treat Options Oncol; 2017 Aug; 18(8):51. PubMed ID: 28785997 [TBL] [Abstract][Full Text] [Related]
19. Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer. Shien K; Papadimitrakopoulou VA; Wistuba II Lung Cancer; 2016 Sep; 99():79-87. PubMed ID: 27565919 [TBL] [Abstract][Full Text] [Related]
20. [Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment]. Duruisseaux M; Lize-Dufranc C; Badoual C; Bibeau F Ann Pathol; 2017 Feb; 37(1):46-54. PubMed ID: 28131419 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]